Literature DB >> 9612380

Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure.

A Luchner1, T L Stevens, D D Borgeson, M Redfield, C M Wei, J G Porter, J C Burnett.   

Abstract

Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure. We therefore determined left atrial and left ventricular (LV) gene expression and tissue concentration as well as circulating BNP during the evolution of rapid ventricular pacing-induced congestive heart failure (CHF) in the dog. Early LV dysfunction after 10 days of pacing was characterized by impaired LV function but maintained arterial pressure, and overt CHF after 38 days of pacing was characterized by further impaired LV function and decreased systemic arterial pressure. Under normal conditions, cardiac BNP mRNA and cardiac tissue BNP were of atrial origin. In early LV dysfunction, BNP mRNA and tissue BNP were markedly increased in the left atrium in association with an increase in circulating BNP but remained below or at the limit of detection in the LV. In overt CHF, BNP mRNA was further increased in the left atrium and first increased in the LV, together with an increase in LV tissue BNP and a further increase in circulating BNP. In the progression of CHF, early LV dysfunction is characterized by a selective increase in atrial BNP expression in association with increased circulating BNP. Overt CHF is characterized by an additional recruitment of ventricular BNP expression and a further increase in circulating BNP. These studies provide important new insight into the local and temporal regulation of cardiac BNP gene expression during the progression of heart failure and underscore the predominant endocrine role of atrial myocardium under normal conditions and in early LV dysfunction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9612380     DOI: 10.1152/ajpheart.1998.274.5.H1684

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  43 in total

Review 1.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

2.  Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats.

Authors:  Sanda Despa; Kenneth B Margulies; Le Chen; Anne A Knowlton; Peter J Havel; Heinrich Taegtmeyer; Donald M Bers; Florin Despa
Journal:  Circ Res       Date:  2012-01-24       Impact factor: 17.367

Review 3.  Reversal of maladaptive gene program in left ventricular myocardium of dogs with heart failure following long-term therapy with the Acorn Cardiac Support Device.

Authors:  Sharad Rastogi; Sudhish Mishra; Ramesh C Gupta; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

4.  Effects of exercise training on pathological cardiac hypertrophy related gene expression and apoptosis.

Authors:  Young I Lee; Joon Y Cho; Mun H Kim; Kee B Kim; Dong J Lee; Kyu S Lee
Journal:  Eur J Appl Physiol       Date:  2006-04-01       Impact factor: 3.078

5.  Differential expression of potassium channels and abnormal conduction in experimental tachycardia-induced heart failure.

Authors:  Christoph Birner; Oliver Husser; Andreas Jeron; Munhie Rihm; Sabine Fredersdorf; Markus Resch; Peter Schmid; Dierk Endemann; Günter Riegger; Andreas Luchner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-07       Impact factor: 3.000

6.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

7.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis.

Authors:  Leigh J Ellmers; J W Knowles; H-S Kim; O Smithies; N Maeda; V A Cameron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08       Impact factor: 4.733

Review 9.  Natriuretic peptide-guided therapy: further research required for still-unresolved issues.

Authors:  R De Vecchis; C Esposito; S Cantatrione
Journal:  Herz       Date:  2013-04-17       Impact factor: 1.443

10.  Gene expression of ANP, BNP and ET-1 in the heart of rats during pulmonary embolism.

Authors:  Henrik Gutte; Jytte Oxbøl; Ulrik Sloth Kristoffersen; Jann Mortensen; Andreas Kjaer
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.